We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology
News

Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology

Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology
News

Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eden Biodesign's custom-designed and licensed cGMP manufacturing facility offers fully segregated viral production at a range of scales, using a variety of production technologies and processes, including a platform approach for the production of adenoviruses in stirred tank suspension culture.

Crucell’s comprehensive package of technology and know-how relating to the human PER.C6® cell line provides a safe and cost-effective manufacturing system for high-yield, large-scale production of vaccines, recombinant proteins and gene therapy products.

The addition of Eden Biodesign to Crucell’s preferred vendor network comes about, in part, as a result of the parties having recently worked together to assist a third party company with extremely rapid and cost-effective progression of an adenoviral product into human clinical trials.

Commenting on the agreement, Crawford Brown, Ph.D., CEO of Eden Biodesign said, “We are delighted to strengthen our relationship with Crucell and to be able to offer Eden Biodesign’s services to Crucell’s PER.C6® licensees. We have demonstrated that the combination of Crucell’s proven and valuable technology and Eden Biodesign’s expertise in vaccine and gene therapy development and manufacturing delivers tremendous value to our customers by accelerating progression of products into and through clinical development, while maintaining the ability to scale-up production and achieve a highly attractive cost-of-goods.”
Advertisement